Albini Elisa, Rosini Verdiana, Gargaro Marco, Mondanelli Giada, Belladonna Maria L, Pallotta Maria Teresa, Volpi Claudia, Fallarino Francesca, Macchiarulo Antonio, Antognelli Cinzia, Bianchi Roberta, Vacca Carmine, Puccetti Paolo, Grohmann Ursula, Orabona Ciriana
Department of Experimental Medicine, University of Perugia, Perugia, Italy.
Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
J Cell Mol Med. 2017 Jan;21(1):165-176. doi: 10.1111/jcmm.12954. Epub 2016 Sep 30.
The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) catalyses the initial, rate-limiting step in tryptophan (Trp) degradation, resulting in tryptophan starvation and the production of immunoregulatory kynurenines. IDO1's catalytic function has long been considered as the one mechanism responsible for IDO1-dependent immune suppression by dendritic cells (DCs), which are master regulators of the balance between immunity and tolerance. However, IDO1 also harbours immunoreceptor tyrosine-based inhibitory motifs, (ITIM1 and ITIM2), that, once phosphorylated, bind protein tyrosine phosphatases, (SHP-1 and SHP-2), and thus trigger an immunoregulatory signalling in DCs. This mechanism leads to sustained IDO1 expression, in a feedforward loop, which is particularly important in restraining autoimmunity and chronic inflammation. Yet, under specific conditions requiring that early and protective inflammation be unrelieved, tyrosine-phosphorylated ITIMs will instead bind the suppressor of cytokine signalling 3 (SOCS3), which drives IDO1 proteasomal degradation and shortens the enzyme half-life. To dissect any differential roles of the two IDO1's ITIMs, we generated protein mutants by replacing one or both ITIM-associated tyrosines with phospho-mimicking glutamic acid residues. Although all mutants lost their enzymic activity, the ITIM1 - but not ITIM2 mutant - did bind SHPs and conferred immunosuppressive effects on DCs, making cells capable of restraining an antigen-specific response in vivo. Conversely, the ITIM2 mutant would preferentially bind SOCS3, and IDO1's degradation was accelerated. Thus, it is the selective phosphorylation of either ITIM that controls the duration of IDO1 expression and function, in that it dictates whether enhanced tolerogenic signalling or shutdown of IDO1-dependent events will occur in a local microenvironment.
吲哚胺2,3-双加氧酶1(IDO1)催化色氨酸(Trp)降解的初始限速步骤,导致色氨酸饥饿并产生免疫调节性犬尿氨酸。长期以来,IDO1的催化功能一直被认为是树突状细胞(DC)依赖IDO1的免疫抑制的一种机制,而树突状细胞是免疫和耐受平衡的主要调节者。然而,IDO1还含有基于免疫受体酪氨酸的抑制基序(ITIM1和ITIM2),一旦被磷酸化,就会结合蛋白酪氨酸磷酸酶(SHP-1和SHP-2),从而在DC中触发免疫调节信号。这种机制导致IDO1在一个前馈回路中持续表达,这在抑制自身免疫和慢性炎症方面尤为重要。然而,在需要早期保护性炎症不缓解的特定条件下,酪氨酸磷酸化的ITIMs反而会结合细胞因子信号传导抑制因子3(SOCS3),后者驱动IDO1的蛋白酶体降解并缩短酶的半衰期。为了剖析IDO1的两个ITIMs的不同作用,我们通过用模拟磷酸化的谷氨酸残基取代一个或两个与ITIM相关的酪氨酸来生成蛋白质突变体。尽管所有突变体都失去了酶活性,但ITIM1突变体(而非ITIM2突变体)确实结合了SHP,并赋予DC免疫抑制作用,使细胞能够在体内抑制抗原特异性反应。相反,ITIM2突变体将优先结合SOCS3,并且IDO1的降解会加速。因此,正是任一ITIM的选择性磷酸化控制着IDO1表达和功能的持续时间,因为它决定了在局部微环境中是增强耐受性信号还是关闭IDO1依赖性事件。